Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cell Death & Disease|April 26, 2020
Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancerAlessandro Ottaiano, Luisa Circelli, Angela Lombardi, et al.
European Journal of Medicinal Chemistry|September 30, 2024
Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modificationAnna Maria Trotta, Vincenzo Mazzarella, Michele Roggia, et al.
JCI Insight|March 8, 2023
Reduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a CXCR4Leu317fsX3 mutation causing WHIM syndromeRajesh Kumar, Samantha Milanesi, Martyna Szpakowska, et al.
Heliyon|August 22, 2024
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterizationLuigi Portella, Giulia Bertolini, Giuseppe Guardascione, et al.
Journal for Immunotherapy of Cancer|March 5, 2022
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapiesCaterina Ieranò, Dario Righelli, Crescenzo D'Alterio, et al.
European Journal of Medicinal Chemistry|July 25, 2024
Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sitesAnna Maria Trotta, Stefano Tomassi, Gaetana Di Maiolo, et al.
Cell Death Discovery|March 28, 2026
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cellsFederica Auletta, Caterina Ieranò, Dario Guido Di Febbraro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell CancerSara Santagata, Anna Maria Trotta, Crescenzo D'Alterio, et al.
BMC Cancer|September 11, 2019
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocolAlessandro Ottaiano, Stefania Scala, Nicola Normanno, et al.
Therapeutic Advances in Medical Oncology|April 15, 2021
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocolAlessandro Ottaiano, Stefania Scala, Mariachiara Santorsola, et al.
Pageof 4